Table 1.

Summary of biochemical results with Pegvisomant treatment in clinical trials and observational/retrospective studies in acromegaly

Author	Primary end point	N. of patients	Disease control (%)	Dose of Pegvisomant	Duration of the study
Randomized clinical trials:
Herman-Bonert et al. [28]	IGF-1 normalization	3	100	30–80 mg/weekly	6 weeks
		3	100	10–20 mg/day	3 months
Trainer et al. [29]	Dose-related efficacy	109	10	placebo	33 months
			38	10 mg/day	3 months
			75	15 mg/day	3 months
			82	20 mg/day	3 months
van der Lely et al. [30]	IGF-1 normalization	90	97	–	12 months
		62	92	–	18 months
Drake et al. [31]	IGF-1 normalization	7	100	20 mg/day (median; range 15-40)	24 months
Barkan et al. [32]	IGF-1 normalization	49	78	16 mg/day (mean; range 5-40)	8 months
Colao et al. [26]	IGF-1 normalization	12	75	25 mg/day (median; range 10-40)	12 months
Observational or retrospective studies:
Schreiber et al. [33]	IGF-1 normalization	147	64	16.5 mg/day (mean; range 10-50)	6 months
		102	71		12 months
		39	76		24 months
Higham et al. [34]	IGF-1 normalization	11	95	15 mg/day (median; range 10-60)	91 months
Trainer [35]	IGF-1 normalization	792	62	15 mg/day (median in controlled patients)	60 months
				16 mg/day (median in not controlled patients)
Buchfelder et al. [36]	IGF-1 normalization	273	56	15 mg/day (median)	6 months
		202	71		24 months
		133	71		36 months
		71	65		48 months
		24	58		60 months
Marazuela et al. [37]	IGF-1 normalization	44	84	17 ± 7 mg/day in men 16 ± 8 mg/day in women	23 months (mean)
Garsia Basavilbaso et al. [38]	Duration-related efficacy	28	46	9.6 mg/day (mean)	3 months
			59
					6 months
van der Lely et al. [39]	Safety and efficacy	1288	63	18 mg/day (mean in controlled patients) 20 mg/day (mean in uncontrolled patients)	43 months (mean)